Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Monte Rosa Therapeutics AG has 3 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 3 examiners and 3 art units, indicating separate examination paths across the active portfolio.
KOSTURKO, GEORGE W is the busiest examiner, with 1 pending matter. Counsel should develop matter-specific responses while checking for consistent claim and disclosure positions across the biotechnology matters.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Double-patenting + other | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KOSTURKO, GEORGE W | 1 | 54.6% | +49.0% |
| BARSKY, JARED | 1 | 50.3% | +22.8% |
| HASTINGS, ALISON AZAR | 1 | 62.5% | +42.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18471563 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | HASTINGS, ALISON AZAR | 6d |
| 18640987 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | KOSTURKO, GEORGE W | — |
| 18485766 | ISOINDOLINONE COMPOUNDS | BARSKY, JARED | — |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| 1628 | 1 |
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18640987 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | KOSTURKO, GEORGE W | 1621 | §102DP | Non-Final OA | — | Pending | Apr 19, 2024 |
| 18485766 | ISOINDOLINONE COMPOUNDS | BARSKY, JARED | 1628 | §112DP | Non-Final OA | — | Pending | Oct 12, 2023 |
| 18471563 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | HASTINGS, ALISON AZAR | 1627 | §103 | Final Rejection | 6d | Pending | Sep 21, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMonte Rosa Therapeutics AG has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
George W Kosturko has the most, with 1 of Monte Rosa Therapeutics AG's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
